Literature DB >> 12714454

Failures of the therapeutic chain as a cause of drug ineffectiveness.

Albert Figueras, Joan-Ramon Laporte.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12714454      PMCID： PMC1125813          DOI： 10.1136/bmj.326.7395.895

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Company played down drug's risks, report says.

Authors:  S Gottlieb
Journal:  BMJ       Date:  2001-03-24

2.  Are clinical trials of therapeutic agents for MS long enough?

Authors:  P Rudge
Journal:  Lancet       Date:  1999-03-27       Impact factor: 79.321

3.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

Review 4.  Alosetron: a case study in regulatory capture, or a victory for patients' rights?

Authors:  Ray Moynihan
Journal:  BMJ       Date:  2002-09-14

5.  Bovine gangliosides and acute motor polyneuropathy.

Authors:  A Figueras; F J Morales-Olivas; D Capellà; V Palop; J R Laporte
Journal:  BMJ       Date:  1992-11-28

6.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

7.  Newly licensed drugs.

Authors:  R E Ferner
Journal:  BMJ       Date:  1996-11-09

8.  Useless drugs are not placebos.

Authors:  J R Laporte; D Capellà
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

9.  Second-generation clinical pharmacology.

Authors:  G Tognoni; M Bonati
Journal:  Lancet       Date:  1986-11-01       Impact factor: 79.321

Review 10.  The effect of pharmaceutical benefits managers: is it being evaluated?

Authors:  K A Schulman; L E Rubenstein; D R Abernethy; D M Seils; D P Sulmasy
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391
  10 in total
  6 in total

1.  Information from drug companies and opinion leaders.

Authors:  Alessandro Liberati; Nicola Magrini
Journal:  BMJ       Date:  2003-05-31

2.  Promotional methods used by representatives of drug companies: a prospective survey in general practice.

Authors:  Jesper Schramm; Morten Andersen; Kirstin Vach; Jakob Kragstrup; Jens Peter Kampmann; Jens Søndergaard
Journal:  Scand J Prim Health Care       Date:  2007-06       Impact factor: 2.581

3.  Cost of medication errors in rheumatic patients in Mexico.

Authors:  Francisco Javier Aceves-Avila; Verónica Benites-Godínez; César Ramos-Remus
Journal:  Clin Rheumatol       Date:  2011-09-21       Impact factor: 2.980

4.  Potential Process Control Issues with Remdesivir.

Authors:  Philip J Almeter; James T Isaacs; Erin E Schuler; Robert A Lodder
Journal:  Contact Context       Date:  2021

5.  Randomised controlled trials for evaluating the prescribing impact of information meetings led by pharmacists and of new information formats, in General Practice in Italy.

Authors:  Nicola Magrini; Giulio Formoso; Anna Maria Marata; Oreste Capelli; Emilio Maestri; Claudio Voci; Francesco Nonino; Massimo Brunetti; Barbara Paltrinieri; Susanna Maltoni; Lucia Magnano; Maria Isabella Bonacini; Lisa Daya; Nilla Viani
Journal:  BMC Health Serv Res       Date:  2007-09-28       Impact factor: 2.655

6.  Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting.

Authors:  Ronald Kiguba; Helen Byomire Ndagije; Victoria Nambasa; Leonard Manirakiza; Elijah Kirabira; Allan Serwanga; Sten Olsson; Niko Speybroeck; Jackson Mukonzo
Journal:  Malar J       Date:  2020-11-03       Impact factor: 2.979
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.